Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Raised to Overweight at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald upgraded Monopar Therapeutics to Overweight from Neutral, setting a $119 price target—about 67.9% above the prior close.
• Analyst sentiment is Moderate Buy, with a consensus target of $122.78; seven analysts rate the stock Buy, one Hold, and one Sell.
• Shares fell 1.2% to $70.88 in Thursday trading. The company reported a quarterly loss of $0.72 per share, narrower than analysts’ expected loss of $0.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was upgraded by research analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating in a research note issued on Thursday, Marketbeat.com reports. The brokerage currently has a $119.00 target price on the stock. Cantor Fitzgerald's price objective would suggest a potential upside of 67.90% from the stock's previous close.

Several other analysts have also recently weighed in on MNPR. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research report on Thursday, July 23rd. Zacks Research downgraded Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 13th. Morgan Stanley restated an "overweight" rating and issued a $130.00 price target on shares of Monopar Therapeutics in a research note on Monday, August 17th. BTIG Research upped their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Monopar Therapeutics in a research report on Thursday, October 15th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $122.78.

Monopar Therapeutics Stock Down 1.2%

NASDAQ:MNPR traded down $0.85 during midday trading on Thursday, hitting $70.88. The company had a trading volume of 189,458 shares, compared to its average volume of 202,720. The company has a market capitalization of $475.71 million, a PE ratio of -32.72 and a beta of 1.62. Monopar Therapeutics has a 52-week low of $50.07 and a 52-week high of $124.82. The stock's fifty day moving average price is $84.40 and its 200-day moving average price is $77.39.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $0.10. As a group, research analysts forecast that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 4,090 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the transaction, the director directly owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher M. Starr sold 8,400 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total transaction of $659,400.00. Following the completion of the sale, the director owned 5,173 shares of the company's stock, valued at approximately $406,080.50. This trade represents a 61.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 51,920 shares of company stock valued at $4,527,913 in the last ninety days. Company insiders own 9.70% of the company's stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in MNPR. Meeder Asset Management Inc. boosted its stake in Monopar Therapeutics by 18.9% during the third quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company's stock worth $132,000 after buying an additional 262 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Monopar Therapeutics during the first quarter worth approximately $250,000. Sei Investments Co. increased its stake in shares of Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company's stock worth $415,000 after buying an additional 656 shares during the period. Bank of America Corp DE raised its holdings in Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock valued at $3,271,000 after acquiring an additional 53,336 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Monopar Therapeutics in the first quarter valued at approximately $3,458,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.